Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22

Benzinga Newsdesk www.benzinga.com Positive 61.2%

Neg 0% Neu 0% Pos 61.2%

Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $22.